SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-003855
Filing Date
2024-01-08
Accepted
2024-01-08 07:00:55
Documents
13
Period of Report
2024-01-05
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d111539d8k.htm   iXBRL 8-K 27854
2 EX-3.1 d111539dex31.htm EX-3.1 7978
  Complete submission text file 0001193125-24-003855.txt   164689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20240105.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20240105_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20240105_pre.xml EX-101.PRE 11708
7 EXTRACTED XBRL INSTANCE DOCUMENT d111539d8k_htm.xml XML 3631
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 24518274
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)